Pharmacy Availability of Buprenorphine for Opioid Use Disorder Treatment in the US.
作者信息
Weiner Scott G, Qato Dima M, Faust Jeremy Samuel, Clear Brian
机构信息
Bicycle Health Inc, Boston, Massachusetts.
Program on Medicines and Public Health, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles.
出版信息
JAMA Netw Open. 2023 May 1;6(5):e2316089. doi: 10.1001/jamanetworkopen.2023.16089.
Abstract
摘要
相似文献
1
Pharmacy Availability of Buprenorphine for Opioid Use Disorder Treatment in the US.
JAMA Netw Open. 2023 May 1;6(5):e2316089. doi: 10.1001/jamanetworkopen.2023.16089.
2
Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden.
Drug Alcohol Depend. 2021 Jul 1;224:108729. doi: 10.1016/j.drugalcdep.2021.108729. Epub 2021 Apr 24.
3
Patient satisfaction with clinic-based medication pick up: Addressing pharmacy-level challenges to buprenorphine access.
J Opioid Manag. 2021;17(7):77-86. doi: 10.5055/jom.2021.0645.
4
Expanded buprenorphine prescribing privileges: Sandbagging in the midst of the flood?
Res Social Adm Pharm. 2018 Jun;14(6):617-618. doi: 10.1016/j.sapharm.2018.03.001. Epub 2018 Mar 3.
5
Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.
J Am Pharm Assoc (2003). 2005 Jan-Feb;45(1):23-32. doi: 10.1331/1544345052843200.
6
Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
JAMA Netw Open. 2021 Apr 1;4(4):e216147. doi: 10.1001/jamanetworkopen.2021.6147.
7
Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes.
J Subst Abuse Treat. 2021 Apr;123:108256. doi: 10.1016/j.jsat.2020.108256. Epub 2020 Dec 18.
8
Pharmacy-based expansion of buprenorphine access.
J Subst Use Addict Treat. 2024 Feb;157:209195. doi: 10.1016/j.josat.2023.209195. Epub 2023 Oct 17.
9
Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
Harm Reduct J. 2022 Jun 29;19(1):69. doi: 10.1186/s12954-022-00651-3.
10
Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
Subst Abus. 2020;41(3):269-274. doi: 10.1080/08897077.2020.1787300.
引用本文的文献
1
Pharmacy Barriers to Receiving Buprenorphine Among Patients Undergoing Telemedicine Addiction Treatment.
JAMA Netw Open. 2025 Aug 1;8(8):e2527418. doi: 10.1001/jamanetworkopen.2025.27418.
2
Addressing wholesale distributor barriers to buprenorphine access: Consensus recommendations from the PhARM-OUD expert panel.
Drug Alcohol Depend Rep. 2025 Jul 10;16:100360. doi: 10.1016/j.dadr.2025.100360. eCollection 2025 Sep.
3
Early findings on home delivery of buprenorphine and retention in treatment for opioid use disorder.
Addict Sci Clin Pract. 2025 Feb 12;20(1):14. doi: 10.1186/s13722-025-00545-2.
4
Barriers to and facilitators of buprenorphine dispensing for opioid use disorder: Evidence from focus groups in Appalachian Kentucky.
J Am Pharm Assoc (2003). 2025 Mar-Apr;65(2):102308. doi: 10.1016/j.japh.2024.102308. Epub 2024 Dec 4.
5
Implementation of a rural emergency department-initiated buprenorphine program in the mountain west: a study protocol.
Addict Sci Clin Pract. 2024 Sep 3;19(1):63. doi: 10.1186/s13722-024-00496-0.
6
Association of economic and racial segregation with restricted buprenorphine dispensing in U.S. community pharmacies.
Drug Alcohol Depend Rep. 2024 Jul 14;12:100255. doi: 10.1016/j.dadr.2024.100255. eCollection 2024 Sep.
7
Opioid Overdose After Medication for Opioid Use Disorder Initiation Following Hospitalization or ED Visit.
JAMA Netw Open. 2024 Jul 1;7(7):e2423954. doi: 10.1001/jamanetworkopen.2024.23954.
8
Assessing suboxone access in community pharmacies: Secret shopper model.
Explor Res Clin Soc Pharm. 2023 Nov 3;12:100356. doi: 10.1016/j.rcsop.2023.100356. eCollection 2023 Dec.
本文引用的文献
1
Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic.
JAMA Netw Open. 2022 Oct 3;5(10):e2236298. doi: 10.1001/jamanetworkopen.2022.36298.
2
Federal and State Pharmacy Regulations and Dispensing Barriers to Buprenorphine Access at Retail Pharmacies in the US.
JAMA Health Forum. 2022 Aug 5;3(8):e222839. doi: 10.1001/jamahealthforum.2022.2839.
3
Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden.
Drug Alcohol Depend. 2021 Jul 1;224:108729. doi: 10.1016/j.drugalcdep.2021.108729. Epub 2021 Apr 24.
4
Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality: An Audit Study.
Ann Intern Med. 2019 Jul 2;171(1):1-9. doi: 10.7326/M18-3457. Epub 2019 Jun 4.
Zotero 插件